Maze Therapeutics (NASDAQ: MAZE) director shows no stock or derivative holdings

Rhea-AI Filing Summary

Maze Therapeutics, Inc. (MAZE) reported that Sophie Kornowski filed an initial statement of beneficial ownership as a director on a Form 3. The filing lists no equity transactions, no derivative positions, and no reported share holdings, serving only to establish her status as an insider.

FAQ

What does the Form 3 filed for MAZE by Sophie Kornowski indicate?

The Form 3 for MAZE indicates that Sophie Kornowski is a director of Maze Therapeutics, Inc. It reports no transactions, no derivative positions, and no share holdings, functioning solely as her initial insider ownership statement.

Does the MAZE Form 3 show any stock purchases or sales by Sophie Kornowski?

No. The MAZE Form 3 shows no reported purchases or sales by Sophie Kornowski. The transaction section is empty and the transaction summary lists zero buy and sell shares, indicating no trading activity is disclosed.

Are any MAZE shares or derivatives reported as owned by Sophie Kornowski on this Form 3?

No. The Form 3 reports no share holdings and no derivative positions for Sophie Kornowski. Summary fields show zero holdings and the derivative section is empty, so no specific MAZE securities are listed as beneficially owned.

What insider role does Sophie Kornowski have at Maze Therapeutics (MAZE)?

According to the Form 3, Sophie Kornowski is reported as a director of Maze Therapeutics, Inc. She is not identified as an officer or a ten-percent owner, making her an insider solely by virtue of serving on the board.

Does the MAZE Form 3 reference any Rule 10b5-1 trading plan for Sophie Kornowski?

No. The Form 3’s plan-status field is null, and there are no footnotes describing a Rule 10b5-1 or other pre-arranged trading plan. Combined with zero transactions, there is no plan-related trading activity disclosed.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Understanding Insider Trading Forms →

Available on EDGAR 08/17/2026 - 04:49 PM Accepted by SEC EDGAR 08/17/2026 - 04:48 PM Learn about SEC filing dates

SEC Form 3

FORM 3

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

INITIAL STATEMENT OF BENEFICIAL OWNERSHIP OF SECURITIES

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0104
Estimated average burden
hours per response:			0.5

1. Name and Address of Reporting Person^*

Kornowski Sophie

(Last) (First) (Middle)

C/O MAZE THERAPEUTICS, INC.

171 OYSTER POINT BOULEVARD, SUITE 300

(Street)

SOUTH SAN FRANCISCO CALIFORNIA 94080

(City) (State) (Zip)

UNITED STATES

(Country)

2. Date of Event Requiring Statement (Month/Day/Year)
08/13/2026

3. Issuer Name and Ticker or Trading Symbol
Maze Therapeutics, Inc. [ MAZE ]

3a. Foreign Trading Symbol

5. If Amendment, Date of Original Filed (Month/Day/Year)

4. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Beneficially Owned
1. Title of Security (Instr. 4)	2. Amount of Securities Beneficially Owned (Instr. 4)	3. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	4. Nature of Indirect Beneficial Ownership (Instr. 5)

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 4)	2. Date Exercisable and Expiration Date (Month/Day/Year)		3. Title and Amount of Securities Underlying Derivative Security (Instr. 4)		4. Conversion or Exercise Price of Derivative Security	5. Ownership Form: Direct (D) or Indirect (I) (Instr. 5)	6. Nature of Indirect Beneficial Ownership (Instr. 5)
	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

No securities are beneficially owned.

	/s/ Courtney Phillips, as attorney-in-fact	08/17/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 5 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 3: SEC 1473 (03-26)